Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.60 |
| ▸ | HTR2A | P28223 | 6/20 | 0.60 |
| ▸ | HTR1A | P08908 | 6/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5454025 | 0.99 | HTR6 (0.59) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL5159659 | 0.91 | HTR6 (0.68) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL5161801 | 0.90 | HTR6 (0.67) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14373090 | 0.85 | HTR6 (0.62) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14373101 | 0.85 | HTR6 (0.62) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14373093 | 0.85 | HTR6 (0.62) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3562663 | 0.84 | HTR6 (0.82) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3566662 | 0.82 | HTR6 (0.81) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14373099 | 0.80 | HTR6 (0.64) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3568712 | 0.79 | HTR6 (0.60) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR3B, HTR1A | HTR6 1/4885HTR2A 6/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.